Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "certificate of analysis"

Looking for quality documents?
external link icon
Repligen Announces Conference Call to Discuss Phase 3 Clinical Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9th, 8:30 a.m. EST
news icon
Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands
news icon
Repligen Corporation & Univercells Technologies Partner to Enable Real-Time Monitoring of Viral Vector and Vaccine Biomanufacturing
event icon
Dynamic Dialysis: A Novel Method for Process Scale Membrane Separation
Learn how the SpectraFlo™ Dynamic Dialysis System accelerates membrane separation of fragile proteins, viscous fluids and polymer gels, such as hyaluronic acid. September 24, 2018 | 24 minutes
external link icon
Repligen Hires Ralf Kuriyel as Senior Vice President of Research & Development
WALTHAM, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the appointment of Ralf Kuriyel to the position of Senior Vice President of Research & Development (R&D). Mr. Kuriyel was most recently Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (Pall), a global leader in the high-tech filtration, separation and purification markets, whose acquisition by Danaher Corporation was completed in August 2015. During his 11-year tenure at Pall, Mr. Kuriyel played a key role in expanding the Global Applications R&D function to include cell culture and single-use applications, process monitoring technologies, and process development services. Prior to Pall, Mr. Kuriyel held various technology and applications development management roles within the bioprocess and biopharm divisions of Millipore
external link icon
Repligen Announces Extension of Long Term Supply Agreement for Protein A
WALTHAM, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has extended through 2019 a key long-term supply agreement with GE Healthcare for the manufacture of Protein A ligands at the Company’s facility in Lund, Sweden. In extending this agreement, the Company aligned important manufacturing and supply terms with its existing GE Healthcare long-term supply agreement, which runs through 2021, for production out of the Company’s Waltham, MA facility. The combined agreements maintain Repligen as the main strategic supplier of recombinant and native forms of Protein A ligands to GE Healthcare. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “This agreement ensures the supply of high quality Protein A ligands to GE Healthcare. Our longtime collaboration is supported by Repligen’s business continuity plans, quality systems and access to our research and development team. We are proud of our Protein A manufacturing
external link icon
Repligen Announces FDA Grant of Priority Review for SecreFlo™ NDA
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2012 Results
external link icon
Repligen Announces Conference Call of First Quarter Fiscal Year 2012 Results
external link icon
Repligen Announces Conference Call of Third Quarter Fiscal Year 2011 Results